WOBURN, MA--(Marketwire - Oct 9, 2012) - For couples attempting to conceive, there are few things more disheartening than the thought one or both partners might be infertile. While infertility is a very real problem for many men and women, there are numerous medical procedures that offer hope to those couples desiring to conceive -- with in vitro fertilization, or IVF, ranking high on the list. According to a recent medical study, IVF techniques may become even more effective in the near future; that study has won the attention, and the affirmation, of ReproSource.
The study in question suggests that a certain chemical can be used to inhibit the PTEN molecule, but also to initiate the transformation of small eggs into healthier, more mature ones. The study was conducted using laboratory mice, with five offspring being born from matured eggs, aided by the PTEN inhibitor. The researchers who conducted the study say that these results offer hope that one day the same procedure can be used for humans to activate and mature small eggs in a Petri dish as part of an IVF treatment.
The study and its surprising findings have won the attention of ReproSource. A clinical research facility that specializes in the field of human fertility, ReproSource has long been zealous for improving existing methods of IVF. The company has responded to the study with a new statement to the press, offering enthusiasm and speculation about where IVF studies might go next.
"This is promising new research for fertility specialists and patients," comments Charles Jenkins, Vice President of ReproSource. "Advancements in this area of in vitro maturation and in the area of fertility preservation have been numerous in recent years. Improved tissue freezing techniques, for example, are providing patients with more reliable options for preserving their fertility in the event that they must undergo life-saving medical treatments that may unfortunately carry the side effect of reduced fertility."
Jenkins continues the ReproSource press statement by looking to the future. "If future studies with this PTEN inhibitor continue to show an ability to assist in the maturation of good quality eggs, there may be applications for patients presenting with a variety of egg supply or egg quality issues," notes the ReproSource Vice President.
Many of the comments from the study's researchers echo Jenkins' remarks, with some of the scientists involved saying that these new findings could potentially have big implications for women with small, immature eggs who are seeking IVF.
ReproSource is a clinical research organization and fertility laboratory, founded in 2008 and passionate for educating patients and healthcare providers alike about the available options for fertility testing and treatment. Jenkins notes that ReproSource's Ovarian Assessment Report is used by fertility specialists and patients around the world to better understand a woman's egg supply.
ReproSource is a clinical laboratory and research organization that exists to provide clinicians and patients alike with the best solutions for fertility testing and education. The organization was founded in 2008 by internationally renowned experts in the areas of diagnostic research, clinical laboratory medicine, and the practice of fertility medicine.